POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
Clinical safety rating
safeNo significant drug interactions Can cause hypernatremia and fluid overload.
Potassium chloride is a potassium salt that dissociates in solution to provide potassium ions, essential for maintaining intracellular tonicity, nerve impulse transmission, cardiac, skeletal, and smooth muscle contraction, and acid-base balance. Dextrose is a monosaccharide that provides caloric support and may prevent ketosis. Sodium chloride provides sodium and chloride ions for electrolyte balance.
| Metabolism | Potassium is primarily excreted unchanged by the kidneys. Dextrose is metabolized via glycolysis and oxidative phosphorylation to carbon dioxide and water. Sodium and chloride are excreted by the kidneys. |
| Excretion | Potassium: 90% renal, 10% fecal. Dextrose: metabolized to CO2 and H2O; no significant renal/fecal excretion. Sodium chloride: excreted renally. |
| Half-life | Potassium: 2–3 hours (redistribution phase). Dextrose: 15–20 minutes. Clinical context: half-life reflects rapid redistribution; in renal impairment, potassium elimination is prolonged. |
| Protein binding | Potassium: very low (<2%), not significantly bound to albumin. Dextrose: not bound. Sodium: not bound. |
| Volume of Distribution | Potassium: 0.5–0.7 L/kg (total body water). Dextrose: 0.2–0.3 L/kg (extracellular). Sodium: 0.2 L/kg (extracellular). Clinical meaning: potassium distributes throughout body water; lean body mass influences Vd. |
| Bioavailability | Intravenous: 100% for all components. Oral: not applicable for IV formulation. |
| Onset of Action | Intravenous: immediate for electrolyte correction. Dextrose effect on blood glucose: within 5 minutes. Sodium effect: within minutes. |
| Duration of Action | Potassium: 2–4 hours for serum level changes. Dextrose: 30–60 minutes for glucose elevation. Sodium: 1–2 hours for plasma volume expansion. Clinical note: duration depends on infusion rate and renal function. |
| Molecular Weight | 74.55 |
Intravenous infusion; rate determined by patient's fluid and electrolyte needs; typical maintenance: 0.22% KCl in D5% and 0.2% NaCl at 100-125 mL/hour; potassium replacement: up to 10 mEq/hour via peripheral line, not to exceed 200 mEq/day.
| Dosage form | INJECTABLE |
| Renal impairment | If GFR < 30 mL/min: reduce potassium content or avoid; monitor serum potassium closely; rate not to exceed 5 mEq/hour; maximum daily dose: 50-100 mEq. |
| Liver impairment | No specific dose adjustment for Child-Pugh class A or B; use with caution in severe hepatic impairment (Child-Pugh C) due to risk of hyperkalemia; monitor serum potassium. |
| Pediatric use | Intravenous infusion; dose based on electrolyte deficit and maintenance requirements; typical maintenance: 2-3 mEq/kg/day of potassium; maximum infusion rate: 0.5-1 mEq/kg/hour; concentration not to exceed 40 mEq/L for peripheral lines. |
| Geriatric use | Initiate at lower end of dosing range; monitor renal function and serum potassium frequently; maximum infusion rate: 5 mEq/hour; consider reduced total daily dose if renal impairment present. |
| 1st trimester | Potassium chloride and dextrose/sodium chloride solutions are commonly used in pregnancy for fluid and electrolyte replacement. No evidence of fetal harm; use only if clearly needed. |
| 2nd trimester | Safe when administered as clinically indicated for maternal hydration and electrolyte balance. Monitor maternal electrolytes and fluid status. |
| 3rd trimester | Safe for maternal indications; avoid excessive volume that could cause uterine hypertonus or fetal fluid overload. Use with caution in preeclampsia. |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Placental transfer | Potassium, sodium, chloride, and glucose cross the placenta via active transport and passive diffusion. Concentrations in fetal plasma are regulated by maternal levels. Dextrose crosses readily; maternal hyperglycemia can cause fetal hyperglycemia. |
| Breastfeeding | Potassium, chloride, dextrose, and sodium are normal constituents of breast milk. Infusion of these electrolytes in maternal plasma does not significantly alter milk composition. Compatible with breastfeeding. |
| Lactation Rating | Safe |
| Teratogenic Risk | Potassium chloride and the dextrose/sodium chloride components do not have known teratogenic effects. No increased risk of congenital anomalies reported with appropriate use. However, severe maternal electrolyte imbalances (e.g., hyperkalemia, hyponatremia) during pregnancy may pose fetal risks, including arrhythmias or acidosis. Dextrose administration is generally safe, but maternal hyperglycemia in gestational diabetes may increase fetal risk. Overall, no direct teratogenicity; risks are related to maternal metabolic derangements. |
| Fetal Monitoring | Monitor serum potassium, sodium, glucose, and renal function during prolonged infusion. Assess fluid balance and signs of hyperkalemia (ECG changes, muscle weakness) or hypoglycemia. In pregnancy, monitor fetal heart rate and uterine activity if maternal electrolyte disturbances occur. Watch for signs of fluid overload, especially in preeclampsia or renal impairment. |
| Fertility Effects | No known adverse effects on fertility. This solution is used for hydration and electrolyte replacement; does not contain hormones or known reproductive toxins. However, severe electrolyte imbalances could theoretically affect reproductive function acutely. |
■ FDA Black Box Warning
None
| Common Effects | fluid replacement |
| Serious Effects |
HyperkalemiaHypernatremiaHyperchloremiaHyperglycemiaSignificant fluid overload (e.g., congestive heart failure, severe renal impairment)Anuria or oliguria not due to dehydrationConcurrent use of strong potassium-sparing diuretics (e.g., amiloride, spironolactone, triamterene) without careful monitoring
| Precautions | Use with caution in patients with severe renal insufficiency, cardiac disease, or conditions predisposing to hyperkalemia, Risk of hyperkalemia, particularly in patients with impaired renal function or receiving potassium-sparing diuretics, Extravasation risk: intravenous administration may cause necrosis or phlebitis, Dextrose-containing solutions should be used with caution in patients with diabetes mellitus |
| Food/Dietary | No direct food interactions. However, patients should avoid excessive dietary potassium (e.g., bananas, oranges, potatoes) unless directed by clinician, especially if renal impairment or risk of hyperkalemia. |
| Clinical Pearls | Use with caution in patients with renal impairment, heart failure, or hyperkalemia. Monitor serum potassium and renal function during prolonged therapy. Not suitable for rapid potassium replacement due to low concentration (0.22% KCl = 2 mEq/L). Incompatible with IV medications that require specific carrier fluids. |
| Patient Advice | This solution contains potassium, dextrose (sugar), and salt. It is used to replace fluids and electrolytes. · Tell your healthcare provider if you have kidney disease, heart problems, or are on a low-potassium diet. · You may experience pain or redness at the IV site; report any discomfort. · Do not suddenly stop the infusion without medical advice. |
Loading safety data…